Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.
Frigault MJ, Dietrich J, Gallagher K, Roschewski M, Jordan JT, Forst D, Plotkin SR, Cook D, Casey KS, Lindell KA, Depinho GD, Katsis K, Elder EL, Leick MB, Choi B, Horick N, Preffer F, Saylor M, McAfee S, O'Donnell PV, Spitzer TR, Dey B, DeFilipp Z, El-Jawahri A, Batchelor TT, Maus MV, Chen YB. Frigault MJ, et al. Among authors: plotkin sr. Blood. 2022 Apr 14;139(15):2306-2315. doi: 10.1182/blood.2021014738. Blood. 2022. PMID: 35167655 Free PMC article. Clinical Trial.
Primary nervous-system lymphoma.
Plotkin SR, Batchelor TT. Plotkin SR, et al. Lancet Oncol. 2001 Jun;2(6):354-65. doi: 10.1016/S1470-2045(00)00390-9. Lancet Oncol. 2001. PMID: 11905752 Review.
Primary nervous system lymphoma.
Plotkin SR, Batchelor TT. Plotkin SR, et al. Curr Treat Options Oncol. 2002 Dec;3(6):525-35. doi: 10.1007/s11864-002-0071-7. Curr Treat Options Oncol. 2002. PMID: 12392641 Review.
Peripheral and cranial nerve sheath tumors.
Mrugala MM, Batchelor TT, Plotkin SR. Mrugala MM, et al. Among authors: plotkin sr. Curr Opin Neurol. 2005 Oct;18(5):604-10. doi: 10.1097/01.wco.0000179507.51647.02. Curr Opin Neurol. 2005. PMID: 16155448 Review.
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK. Batchelor TT, et al. Among authors: plotkin sr. J Clin Oncol. 2010 Jun 10;28(17):2817-23. doi: 10.1200/JCO.2009.26.3988. Epub 2010 May 10. J Clin Oncol. 2010. PMID: 20458050 Free PMC article. Clinical Trial.
196 results